HIPPO signaling-related signature for predicting prognosis and therapeutic response in gastric cancer

被引:3
作者
Jiang, Rui [1 ]
Wang, Jinghua [2 ]
Liang, Jun [3 ]
Lin, Daihua [4 ]
Mao, Qiuxian [4 ]
Cheng, Siyi [5 ]
Huang, Shengjun [6 ]
Tong, Shuangshuang [7 ]
Lyu, Yanlin [7 ]
Wei, Rui [1 ,8 ]
Lian, Qizhou [9 ,10 ,11 ]
Chen, Hao [1 ,6 ,7 ]
机构
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Gastroenterol, Guangzhou, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China
[3] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Prov Geriatr Inst, Dept Crit Care Med, Guangzhou, Peoples R China
[4] Guangdong Second Prov Gen Hosp, Prenatal Diagnost Ctr, Guangzhou, Peoples R China
[5] South China Univ Technol, Sch Biosci & Bioengn, Guangzhou, Peoples R China
[6] South China Univ Technol, Sch Med, Guangzhou, Peoples R China
[7] Shantou Univ, Med Coll, Shantou, Peoples R China
[8] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China
[9] Chinese Acad Sci, Shenzhen Inst Adv Technol, Fac Synthet Biol, Shenzhen, Peoples R China
[10] Guangzhou Med Univ, Guangzhou Inst Eugenics & Perinatol, Guangzhou Women & Childrens Med Ctr, Cord Blood Bank, Guangzhou, Peoples R China
[11] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China
基金
中国国家自然科学基金;
关键词
gastric cancer; hippo signaling pathway; prognostic prediction; drug sensitivity analysis; therapeutic response; BETA ISOFORMS; PATHWAY; CELLS; PROLIFERATION; BORTEZOMIB; TARGET;
D O I
10.3389/fphar.2022.1096055
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Gastric cancer (GC) is a multifactorial progressive disease with high mortality and heterogeneous prognosis. Effective prognostic biomarkers for GC were critically needed. Hippo signaling pathway is one of the critical mechanisms regulating the occurrence and development of GC, and has potential clinical application value for the prognosis and treatment of GC patients. However, there is no effective signature based on Hippo signaling pathway-related genes (HSPRGs) to predict the prognosis and treatment response of GC patients. Our study aimed to build a HSPRGs signature and explore its performance in improving prognostic assessment and drug therapeutic response in GC.Methods: Based on gene expression profiles obtained from The Cancer Genome Atlas (TCGA) database, we identified differentially expressed HSPRGs and conducted univariate and the least absolute shrinkage and selection operator (LASSO) Cox regression analysis to construct a multigene risk signature. Subsequently, the Kaplan-Meier curve and receiver operating characteristic (ROC) were performed to evaluate the predictive value of the risk signature in both training and validation cohort. Furthermore, we carried out univariate and multivariate Cox regression analysis to investigate the independent prognostic factors and establish a predictive nomogram. The enriched signaling pathways in risk signature were analyzed by gene set enrichment analysis (GSEA). Tumor immune dysfunction and exclusion (TIDE) and drug sensitivity analysis were performed to depict therapeutic response in GC.Results: In total, 38 differentially expressed HSPRGs were identified, and final four genes (DLG3, TGFB3, TGFBR1, FZD6) were incorporated to build the signature. The ROC curve with average 1-, 3-, and 5-year areas under the curve (AUC) equal to .609, .634, and .639. Clinical ROC curve revealed that risk signature was superior to other clinicopathological factors in predicting prognosis. Calibration curves and C-index (.655) of nomogram showed excellent consistency. Besides, in the immunotherapy analysis, exclusion (p < 2.22 x 10(-16)) and microsatellite instability (p = .0058) performed significantly differences. Finally, our results suggested that patients in the high-risk group were more sensitive to specific chemotherapeutic agents.Conclusion: Results support the hypothesis that Hippo-related signature is a novel prognostic biomarker and predictor, which could help optimize GC prognostic stratification and inform clinical medication decisions.
引用
收藏
页数:11
相关论文
共 50 条
[41]   A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer [J].
Cai, Jinming ;
Xie, Haoran ;
Yan, Yilin ;
Huang, Zhengnan ;
Tang, Pengfei ;
Cao, Xiangqian ;
Wang, Zeyi ;
Yang, Chenkai ;
Wen, Jiling ;
Tan, Mingyue ;
Zhang, Fang ;
Shen, Bing .
FRONTIERS IN GENETICS, 2023, 13
[42]   Gastric cancer peritoneal metastasis related signature predicts prognosis and sensitivity to immunotherapy in gastric cancer [J].
Sun, YuQin ;
Chen, YueQing ;
Zhuang, Wei ;
Fang, ShunYong ;
Chen, QiuXian ;
Lian, MingQiao ;
Lv, ChenBin ;
Weng, JianMing ;
Wei, Ran ;
Lin, Yao ;
Cai, LiSheng ;
Wang, QingShui .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (22) :3578-3590
[43]   Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer [J].
He, Xudong ;
Gu, Yun ;
Cao, Yifan ;
Hu, Baoying ;
Fang, Hanji ;
Fei, Yuchao ;
Lv, Kunpeng ;
Liu, Xin ;
Wang, Jieti ;
Lin, Chao ;
Liu, Hao ;
Zhang, Heng ;
Li, He ;
Li, Ruochen ;
He, Hongyong ;
Xu, Jiejie .
EUROPEAN JOURNAL OF CANCER, 2021, 157 :114-123
[44]   Development of anoikis-related genes signature to predict the prognosis in gastric cancer patients [J].
Cao, Jie ;
Hong, Kai ;
Cao, Yuepeng ;
Cen, Kenan ;
Mai, Yifeng ;
Dai, Ying ;
Ouyang, Guifang ;
Mu, Qitian ;
Guo, Yangyang .
FRONTIERS IN ONCOLOGY, 2023, 12
[45]   Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients [J].
Jun-Mei Wang ;
Xuan Li ;
Peng Yang ;
Wen-Bin Geng ;
Xiao-Yong Wang .
BMC Gastroenterology, 22
[46]   Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients [J].
Wang, Jun-Mei ;
Li, Xuan ;
Yang, Peng ;
Geng, Wen-Bin ;
Wang, Xiao-Yong .
BMC GASTROENTEROLOGY, 2022, 22 (01)
[47]   Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer [J].
Pei, Jun-Peng ;
Zhang, Chun-Dong ;
Yusupu, Maimaititusun ;
Zhang, Cheng ;
Dai, Dong-Qiu .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[48]   A novel N7-methylguanosine-related long noncoding RNAs signature for predicting prognosis and immune microenvironment in gastric cancer patients [J].
Guo, Peisen ;
Wang, Panpan ;
Liu, Limin ;
Wang, Peixi ;
Qu, Zhi ;
Yu, Zengli ;
Liu, Nan .
PRECISION MEDICAL SCIENCES, 2022, 11 (04) :195-208
[49]   Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer [J].
Cui, Hanxiao ;
Ren, Xueting ;
Dai, Luyao ;
Chang, Lidan ;
Liu, Dandan ;
Zhai, Zhen ;
Kang, Huafeng ;
Ma, Xiaobin .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[50]   Development of a metabolism-related signature for predicting prognosis, immune infiltration and immunotherapy response in breast cancer [J].
Li, Chunzhen ;
Tao, Yijie ;
Chen, Yining ;
Wu, Yunyang ;
He, Yixian ;
Yin, Shulei ;
Xu, Sheng ;
Yu, Yizhi .
AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (12) :5440-+